Last reviewed · How we verify
ACEI/ARB
ACEI/ARB drugs inhibit the renin-angiotensin-aldosterone system (RAAS) to reduce blood pressure and protect organs from hypertension-related damage.
ACE inhibitors and ARBs lower blood pressure by blocking the renin-angiotensin-aldosterone system, either by inhibiting angiotensin-converting enzyme or blocking angiotensin II type 1 receptors. Used for Pediatric hypertension, Chronic kidney disease in children, Heart failure in pediatric patients.
At a glance
| Generic name | ACEI/ARB |
|---|---|
| Also known as | benazepril, captopril, enalapril, fosinopril, lisinopril |
| Sponsor | Capital Institute of Pediatrics, China |
| Drug class | ACE inhibitor / Angiotensin II receptor blocker |
| Target | ACE enzyme / Angiotensin II type 1 receptor (AT1R) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
ACE inhibitors block the conversion of angiotensin I to angiotensin II, while ARBs (angiotensin II receptor blockers) directly antagonize angiotensin II type 1 receptors. Both classes reduce vasoconstriction and aldosterone secretion, lowering blood pressure and reducing cardiac and renal workload. These drugs are particularly beneficial in patients with hypertension, heart failure, and chronic kidney disease.
Approved indications
- Hypertension
- Heart failure
- Chronic kidney disease
- Post-myocardial infarction cardioprotection
Common side effects
- Cough (ACE inhibitors)
- Hyperkalemia
- Dizziness
- Angioedema
- Hypotension
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease (PHASE1, PHASE2)
- Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
- Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN (PHASE2)
- Venous Congestion And Cognitive Dysfunction After Cardiac Surgery
- A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria (PHASE3)
- The GUARDIAN Pilot Trial (NA)
- A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACEI/ARB CI brief — competitive landscape report
- ACEI/ARB updates RSS · CI watch RSS
- Capital Institute of Pediatrics, China portfolio CI